These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 7750045)

  • 21. [Dyslipidemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy].
    Martínez-Castelao A; Ramos R; González MT; Castiñeiras MJ
    Nefrologia; 2002; 22 Suppl 1():51-8. PubMed ID: 11987671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statin therapy for the treatment of diabetic dyslipidemia.
    Haffner SM
    Diabetes Metab Res Rev; 2003; 19(4):280-7. PubMed ID: 12879405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes.
    Goldberg RB
    Am J Manag Care; 2000 Aug; 6(13 Suppl):S682-91; discussion S692-6. PubMed ID: 11183421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid abnormalities in insulin resistant states.
    Watson KE; Horowitz BN; Matson G
    Rev Cardiovasc Med; 2003; 4(4):228-36. PubMed ID: 14668690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.
    Ali YS; Linton MF; Fazio S
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):142-6. PubMed ID: 18316949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease.
    Koga H; Sugiyama S; Kugiyama K; Fukushima H; Watanabe K; Sakamoto T; Yoshimura M; Jinnouchi H; Ogawa H
    Eur Heart J; 2006 Apr; 27(7):817-23. PubMed ID: 16434416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of dyslipoproteinaemia in diabetes mellitus.
    Dean JD; Durrington PN
    Diabet Med; 1996 Apr; 13(4):297-312. PubMed ID: 9162604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperlipidemia in children with type 2 diabetes mellitus.
    Taha D
    J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():505-7. PubMed ID: 12017224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Disorders of lipid metabolism in 3 patients with diabetes mellitus type 2].
    Wolffenbuttel BH; Huijberts MS
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):761-5. PubMed ID: 11346911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
    Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipids in type 2 diabetes.
    Laakso M
    Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of hyperlipoproteinemia in patients with diabetes mellitus].
    Dammann HG; Dreyer M; Wernecke J; Lankers H; Müller P; Simon B
    Fortschr Med; 1990 May; 108(15):305-8. PubMed ID: 2204598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective.
    Toth PP
    Int J Clin Pract; 2009 Jun; 63(6):903-11. PubMed ID: 19490201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperlipidemia and diabetes mellitus.
    O'Brien T; Nguyen TT; Zimmerman BR
    Mayo Clin Proc; 1998 Oct; 73(10):969-76. PubMed ID: 9787748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.